LIWANLI Innovation Co Ltd (3054) - Total Assets
Based on the latest financial reports, LIWANLI Innovation Co Ltd (3054) holds total assets worth NT$776.15 Million TWD (≈ $24.45 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See what is LIWANLI Innovation Co Ltd's book value for net asset value and shareholders' equity analysis.
LIWANLI Innovation Co Ltd - Total Assets Trend (2003–2024)
This chart illustrates how LIWANLI Innovation Co Ltd's total assets have evolved over time, based on quarterly financial data.
LIWANLI Innovation Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
LIWANLI Innovation Co Ltd's total assets of NT$776.15 Million consist of 47.8% current assets and 52.2% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 31.3% |
| Accounts Receivable | NT$8.84 Million | 1.1% |
| Inventory | NT$27.36 Million | 3.5% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2003–2024)
This chart illustrates how LIWANLI Innovation Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 3054 company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: LIWANLI Innovation Co Ltd's current assets represent 47.8% of total assets in 2024, an increase from 0.0% in 2003.
- Cash Position: Cash and equivalents constituted 31.3% of total assets in 2024, up from 12.1% in 2003.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 3.0% in 2003.
- Asset Diversification: The largest asset category is inventory at 3.5% of total assets.
LIWANLI Innovation Co Ltd Competitors by Total Assets
Key competitors of LIWANLI Innovation Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥31.46 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.34 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥15.32 Billion |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
|
China | CN¥10.96 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
LIWANLI Innovation Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 13.30 | 12.75 | 9.10 |
| Quick Ratio | 11.28 | 11.30 | 8.35 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$346.46 Million | NT$380.47 Million | NT$527.49 Million |
LIWANLI Innovation Co Ltd - Advanced Valuation Insights
This section examines the relationship between LIWANLI Innovation Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.66 |
| Latest Market Cap to Assets Ratio | 0.21 |
| Asset Growth Rate (YoY) | -5.0% |
| Total Assets | NT$792.19 Million |
| Market Capitalization | $167.70 Million USD |
Valuation Analysis
Below Book Valuation: The market values LIWANLI Innovation Co Ltd's assets below their book value (0.21x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: LIWANLI Innovation Co Ltd's assets decreased by 5.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for LIWANLI Innovation Co Ltd (2003–2024)
The table below shows the annual total assets of LIWANLI Innovation Co Ltd from 2003 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$792.19 Million ≈ $24.96 Million |
-5.03% |
| 2023-12-31 | NT$834.17 Million ≈ $26.28 Million |
+3.50% |
| 2022-12-31 | NT$805.93 Million ≈ $25.39 Million |
-14.98% |
| 2021-12-31 | NT$947.90 Million ≈ $29.86 Million |
-5.53% |
| 2020-12-31 | NT$1.00 Billion ≈ $31.61 Million |
-11.52% |
| 2019-12-31 | NT$1.13 Billion ≈ $35.73 Million |
+6.80% |
| 2018-12-31 | NT$1.06 Billion ≈ $33.45 Million |
-33.87% |
| 2017-12-31 | NT$1.61 Billion ≈ $50.59 Million |
-7.49% |
| 2016-12-31 | NT$1.74 Billion ≈ $54.68 Million |
+4.62% |
| 2015-12-31 | NT$1.66 Billion ≈ $52.26 Million |
-13.42% |
| 2014-12-31 | NT$1.92 Billion ≈ $60.37 Million |
-10.56% |
| 2013-12-31 | NT$2.14 Billion ≈ $67.49 Million |
+44.52% |
| 2012-12-31 | NT$1.48 Billion ≈ $46.70 Million |
+19.98% |
| 2011-12-31 | NT$1.24 Billion ≈ $38.92 Million |
+20.22% |
| 2010-12-31 | NT$1.03 Billion ≈ $32.38 Million |
-16.72% |
| 2009-12-31 | NT$1.23 Billion ≈ $38.88 Million |
+57.96% |
| 2008-12-31 | NT$781.16 Million ≈ $24.61 Million |
+5.50% |
| 2007-12-31 | NT$740.41 Million ≈ $23.33 Million |
-0.09% |
| 2006-12-31 | NT$741.11 Million ≈ $23.35 Million |
+38.95% |
| 2005-12-31 | NT$533.37 Million ≈ $16.80 Million |
-44.66% |
| 2004-12-31 | NT$963.72 Million ≈ $30.36 Million |
-22.96% |
| 2003-12-31 | NT$1.25 Billion ≈ $39.41 Million |
-- |
About LIWANLI Innovation Co Ltd
LIWANLI Innovation Co., Ltd. operates in the biomedical science industry in Taiwan and internationally. The company offers Vigoway and powder collection products for male, female, elderly, and children. Its products include anti-aging desire, pro-active nutrients capsules, black elderberry powder, probiotic enzymes, oral care tablets, resveratrol red grape extract, algae DHA soft gels, shea butte… Read more